Apart from Speedo swimsuits, what other biomimicry learnings from Shark skin can we use for medical devices?
Involving all aspects of ergonomics—physical, cognitive and emotional—is the only way to create tomorrow’s engaging, enjoyable and appropriate device experiences, while fulfilling functional requirements as well as intangible needs.
True sustainability isn’t about compromise; it is about creating innovative solutions that are not only good for the world, but good for business.
New and Revived: Your questions on adhesives usage answered by Christine Salerni Marotta at Henkel-Loctite.
For the past decade “translational science” and “translational medicine” have been cherished buzzwords, raising the prospect of faster, better, more seamless transfer of discoveries from bench to bedside. Too often, though, it doesn’t work. Differences in the cultures of academia and medical manufacturing, and a poor grasp of regulatory and reimbursement issues, or of what makes a bright idea into a clinically useful, commercially viable product have scuttled more than one promising innovation.
On July 19 and 20, 2010, the Food and Drug Administration held a public meeting on regulatory oversight of laboratory-developed tests (LDTs). This is considered a major step in an ongoing debate on how best to handle two different, but often overlapping, sets of diagnostic tools in a manner that best serves patient safety and public health, while recognizing the realities of clinical practice and medical product development.
Stakeholder interest was intense. The original meeting space reached capacity and registration closed within two days, prompting FDA to shift the conference to a larger venue. Nearly 650 people attended, while 650 more watched via webcast. FDA’s sense of urgency on the matter was further suggested by the June 10 issuance of “it has come to our attention” letters to six genetic testing companies, followed by another 14 on the opening day of the conference itself.
What are the issues? Why the concern? What does it all mean, and where might the Agency go?
The evaluation and management of risk throughout the product life cycle is the single most important concept in the regulation of medical devices. Yet it is difficult to define precisely what “risk” means or how to assess it in an industry where some 115,000 devices are produced by thousands of manufacturers, employing a dizzying array of technologies destined for use in varying health settings for every imaginable indication. So who determines the risk, and where do problems typically arise?
Q: I tried to bond a nylon component to an SLA part, but the adhesive easily peeled off of the nylon even though I used what I thought was a very good adhesive. Any recommendations on how to get these parts bonded together? A: Plastics have different characteristics based on whether their material structure is semi-crystalline or amorphous. Plastics are composed of long polymer chains. In an amorphous structure these polymer chains are tangled together like a plate of spaghetti noodles. Typical ex…